1. Indications and Usage
\nSymptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM): Treatment of adults with New York Heart Association (NYHA) class II-III symptomatic oHCM to improve exercise capacity and symptoms .
\n2. Dosage and Administration
\nAdministration: Oral administration once daily with or without food. Capsules must be swallowed whole .
\nStarting Dose:
\nStandard: 5 mg once daily.
\nCYP2C19 Poor Metabolizers or with Weak CYP2C19\/Mod CYP3A4 Inhibitors: 2.5 mg once daily .
\nDose Adjustment: Dosing is guided by echocardiographic monitoring of Left Ventricular Ejection Fraction (LVEF) and LVOT gradient.
\nIncrease: Consider increasing by one dose level if LVEF \u226555% and LVOT gradient \u226530 mmHg.
\nHold\/Decrease: Interrupt therapy if LVEF <50%. Resume at a lower dose once LVEF recovers to \u226550% .
\nContraindicated Combinations: Do not co-administer with moderate\/strong CYP2C19 inhibitors or strong CYP3A4 inhibitors .
\n3. Mechanism of Action
\nMavacamten is a first-in-class, allosteric, reversible inhibitor of cardiac myosin.
\nIt binds to cardiac myosin and reduces the number of myosin heads available to interact with actin to generate force. This reduces myocardial contractility, decreases the left ventricular outflow tract (LVOT) gradient, and improves ventricular compliance and diastolic filling .
\n4. Safety and Warnings
\nHeart Failure: Mavacamten can cause heart failure by reducing contractility. Monitoring of LVEF is mandatory before initiation and periodically during treatment. Do not initiate therapy if baseline LVEF is <55% .
\nContraindications: Severe hepatic impairment (Child-Pugh Class C) and pregnancy .
\nReproductive Toxicity: May cause fetal harm. Females of reproductive potential must use effective contraception during treatment and for 4 months after the final dose .
\n5. Adverse Reactions
\nCommon (>2%): Heart failure, fatigue, dyspnea, dizziness, nausea, and syncope .
\nSerious: Symptomatic heart failure and severe reduction in LVEF .
\n6. Drug Interactions
\nCytochrome P450 Substrate: Mavacamten is primarily metabolized by CYP2C19 (and CYP3A4).
\nInhibitors: Moderate\/strong CYP2C19 inhibitors (e.g., fluconazole) or strong CYP3A4 inhibitors (e.g., ketoconazole) are prohibited. Weak inhibitors (e.g., fluoxetine) require dose reduction (e.g., start at 2.5 mg) .
\nInducers: Moderate\/strong inducers of CYP2C19 or CYP3A4 (e.g., rifampin, carbamazepine) are contraindicated as they may reduce efficacy .
\n7. Pharmaceutical Information
\nChemical Name: 6-[[(1S)-1-phenylethyl]amino]-3-propyl-1H-pyrimidine-2,4-dione .
\nMolecular Formula: C15H19N3O2 .
\nMolecular Weight: 273.34 .
\nStorage: Store at controlled room temperature (20\u00b0C to 25\u00b0C) .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name:\u8fc8\u51e1\u59a5\u00ae\uff08Camzyos\u00ae\uff09<\/p>\n
Generic Name:Mavacamten<\/p>\n
Strength: 2.5 mg per capsule, 14 capsules per blister, 2 blisters per box (total 28 capsules\/box)<\/p>\n
Manufacturer:Patheon Inc.<\/p>\n
Marketing Authorization Holder:Bristol-Myers Squibb<\/p>\n
Approval Date in China:April 24, 2024<\/p>\n
Registration Number:\u56fd\u836f\u51c6\u5b57HJ20240012<\/p>\n
Storage:Sealed, store at temperature not exceeding 30\u00b0C, keep dry and avoid direct sunlight; retain original packaging.<\/p>\n
Price&Cost:Contact Us now for the best price of Mavacamten\uff08Camzyos\uff09<\/p>\n","protected":false},"featured_media":2830,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[26],"product_tag":[],"class_list":["post-2829","product","type-product","status-publish","has-post-thumbnail","product_cat-capsules","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n